丹参联合黄芩苷对慢性乙型肝炎患者血清肝纤维化标志物影响.docVIP

丹参联合黄芩苷对慢性乙型肝炎患者血清肝纤维化标志物的影响 作者：周耀南，覃后继，何延专，黄重敏，黄其文，覃雪英，黄春合，陆春雷 【摘要】 　　目的 观察丹参联合黄芩苷对慢性乙型肝炎患者血清肝纤维化标志物的影响，探讨慢性乙型肝炎患者抗肝纤维化治疗方法。方法 慢性乙型肝炎患者80例，随机分为两组：治疗组在常规保肝治疗基础上用丹参＋黄芩苷治疗，对照组在常规保肝治疗基础上用丹参治疗。治疗开始前、疗程结束时、疗程结束后1年，分别检测血清肝纤维化标志物：放免法检测血清透明质酸（HA）、层黏蛋白（LN）、Ⅲ型前胶原肽（PCⅢ）、Ⅳ型胶原（ⅣC），酶联免疫吸附法检测血清转移生长因子β1（TGFβ1），同时检测肝功能、B超等。结果 治疗组和对照组疗程结束时血清肝纤维化标志物水平均有下降，与治疗前比较有统计学意义（P＜0.01），但两组之间比较无统计学意义（P＞0.05）；疗程结束后1年治疗组和对照组血清肝纤维化标志物水平仍较低，与治疗前比较仍有统计学意义（P＜0.01），而两组之间比较有统计学意义（P＜0.05）。结论 丹参联合黄芩苷能更有效降低慢性乙型肝炎患者血清肝纤维化标志物水平。 【关键词】 肝纤维化 慢性乙型肝炎 丹参 黄芩苷 　　【Abstract】 Objective To investigate the effect of savlviae combine with baicalin to serum liver fibrosis symbolization in patients with chronic hepatitis B.Methods 80 patients with chronic hepatitis B were randomly divided into treatment group and control group. Teatment group applied savlviae combine with baicalin aside routine liverprotective therapy,control group applied savlviae side routine liverprotective therapy.Serum liver fibrosis symbolizations were detected at the begining,ending and 1 year after the treatment. Hyaluronic,laminin,amino terminal properptide of type Ⅲ procollagen and Ⅳ collagen were detected by radioimmunoassay.Transforming growth factorβ1 was detected by enzyme linked immunosorbent assay.Results Serum liver fibrosis symbolizations level were decreased in both groups at the end of the treatment(P＜0.01).There was no significant deferent in two groups(P＞0.05).1 year after the treatment,Serum liver fibrosis symbolizations level in treatment group were lower than that of control group(P＜0.05).Conclusion Savlviae combine with baicalin could be good for decreasing serum liver fibrosis symbolizations level in patients with chronic hepatitis B. 　　【Key words】 liver fibrosis;chronic hepatitis B;Savlviae;Baicalin 　　全世界约有3.5亿乙型肝炎病毒感染者，其中我国约有1.2亿人。这些感染者中，约25%最终死于重症慢性肝病（慢性重型肝炎）、肝硬化及肝癌。慢性乙型肝炎由于长期反复炎症，引起肝纤维化，导致肝硬化，最终死亡。如果抑制或逆转肝纤维化，就能防止肝硬化，减少慢性乙型肝炎死亡率，这也是目前慢性乙型肝炎治疗研究的热点之一，但目前抗肝纤维化尚无疗效确切的治疗药物。我们通过观察丹参联合黄芩苷对慢性乙型肝炎患者血清肝纤维化标志物的影响，探讨其对慢性乙型肝炎患